Abstract Stargardt’s macular dystrophy (SMD) is an autosomal recessive inherited retinal dystrophy associated with a mutation in the ABCA4 gene. Although there are no current food and drug administration (FDA)-approved treatments or cures for patients with SMD, current research avenues include nutritional supplementation, drug therapies, and gene therapy. It is a rare genetic eye disease that happens when fatty material builds upon the macula.
Rajnandani et al. (Sun,) studied this question.